CORRECTION article

Front. Immunol., 30 April 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1613095

Corrigendum: Harnessing single-cell and multi-omics insights: STING pathway-based predictive signature for immunotherapy response in lung adenocarcinoma

This article is a correction to:

  1. Harnessing Single-cell and Multi-omics Insights: STING Pathway-based Predictive Signature for Immunotherapy Response in Lung Adenocarcinoma

    1. Read original article
Yang Ding&#x;Yang Ding1†Dingli Wang&#x;Dingli Wang2†Dali Yan&#x;Dali Yan3†Jun Fan&#x;Jun Fan4†Zongli Ding*Zongli Ding5*Lei Xue*Lei Xue4*
  • 1Department of Pathology, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, China
  • 2Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
  • 3Department of Oncology, The Affiliated Huai’an Hospital of Xuzhou Medical University and the Second People’s Hospital of Huai’an, Huai’an, China
  • 4Department of Thoracic Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
  • 5Department of Geriatrics, The Affiliated Huai’an Hospital of Xuzhou Medical University and the Second People’s Hospital of Huai’an, Huai’an, China

A Corrigendum on
Harnessing single-cell and multi-omics insights: STING pathway-based predictive signature for immunotherapy response in lung adenocarcinoma

by Yang D, Wang D, Yan D, Fan J, Ding Z and Xue L (2025). Front. Immunol. 16:1575084. doi: 10.3389/fimmu.2025.1575084

In the original article, there was an error in the author list. The first author’s name was incorrectly listed as “Ding Yang” instead of the correct name “Yang Ding”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: non-small cell lung cancer, lung adenocarcinoma, single-cell RNA sequencing, prognosis signature, machine learning

Citation: Ding Y, Wang D, Yan D, Fan J, Ding Z and Xue L (2025) Corrigendum: Harnessing single-cell and multi-omics insights: STING pathway-based predictive signature for immunotherapy response in lung adenocarcinoma. Front. Immunol. 16:1613095. doi: 10.3389/fimmu.2025.1613095

Received: 16 April 2025; Accepted: 17 April 2025;
Published: 30 April 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Ding, Wang, Yan, Fan, Ding and Xue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zongli Ding, em9uZ2xpZGluZzIwMTFAMTI2LmNvbQ==; Lei Xue, bGVpeHVlMTM4NUBuam11LmVkdS5jbg==

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.